• CDC
  • Heart Failure
  • Cardiovascular Clinical Consult
  • Adult Immunization
  • Hepatic Disease
  • Rare Disorders
  • Pediatric Immunization
  • Implementing The Topcon Ocular Telehealth Platform
  • Weight Management
  • Monkeypox
  • Guidelines
  • Men's Health
  • Psychiatry
  • Allergy
  • Nutrition
  • Women's Health
  • Cardiology
  • Substance Use
  • Pediatrics
  • Kidney Disease
  • Genetics
  • Complimentary & Alternative Medicine
  • Dermatology
  • Endocrinology
  • Oral Medicine
  • Otorhinolaryngologic Diseases
  • Pain
  • Gastrointestinal Disorders
  • Geriatrics
  • Infection
  • Musculoskeletal Disorders
  • Obesity
  • Rheumatology
  • Technology
  • Cancer
  • Nephrology
  • Anemia
  • Neurology
  • Pulmonology

Autosomal Dominant Polycystic Kidney Disease: Studies in Comorbidity

Slideshow

Studies on comorbidities seen with CKD reviewed here examine controlled vs uncontrolled gout, psychiatric diagnoses, and screening for intracranial aneurysm.

Comorbidites seen with chronic kidney disease can be devastating. In the slides below we highlight research from recent meetings and the literature on:● Prevalence of chronic kidney disease (CKD) in uncontrolled vs controlled gout ● Psychiatric diagnoses in hospitalized ESKD patients ● Screening for intracranial aneurysms in patients with ADPKD

Related Videos
Where Should SGLT-2 Inhibitor Therapy Begin? Thoughts from Drs Mikhail Kosiborod and Neil Skolnik
Related Content
Advanced-Stage CKD Prevalence Quickly Rising Worldwide: Daily Dose / image credit: ©New Africa/AdobeStock

Advanced-Stage CKD Prevalence Quickly Rising Worldwide: Daily Dose

April 22nd 2024
Article

Your daily dose of the clinical news you may have missed.

Zilebesiran Reduces SBP on Background SOC in Uncontrolled HTN: Daily Dose / image credit: ©New Africa/AdobeStock

Zilebesiran Reduces SBP on Background SOC in Uncontrolled HTN: Daily Dose

April 16th 2024
Article

Your daily dose of the clinical news you may have missed.

©pikovit/stock.adobe.com

Advanced-Stage CKD Prevalence Rising Rapidly Worldwide: Multidimensional Modeling Study

April 15th 2024
Article

The overall CKD population will reach 125 million by 2032 across 8 industrialized nations, with significant clinical, social, economic, and environmental costs.

Elevated Albuminuria, Even Within Normoalbuminuric Range, May Be Linked to Elevated Risk for CKD Progression, Hepatic Failure / image credit kidney disease: ©alxmls/stock.adobe.com

Elevated Albuminuria, Even Within Normoalbuminuric Range, May Be Linked to Elevated Risk for CKD Progression, Renal Failure

April 10th 2024
Article

New study findings raise important questions about how early to initiate therapy to reduce proteinuria and whether even lower levels should be sought to improve CKD outcomes.

Zilebesiran Reduces SBP by Up to 14 mm Hg on Background SOC: KARDIA-2 Analysis at ACC.24 Akshay Desai, MD, MPH

Zilebesiran Reduces SBP by Up to 14 mm Hg on Background SOC in Uncontrolled Hypertension: KARDIA-2

April 8th 2024
Article

ACC.24: Zilebesiran led to clinically and statistically significant reductions in SBP on top of either a diuretic, CCB, or ARB; SQ dosing is every 3-6 months.

FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension in Landmark Decision

FDA Approves Aprocitentan (Tryvio) for Treatment-Resistant Hypertension in Landmark Decision

March 20th 2024
Article

Aprocitentan is the first antihypertensive drug approved in more than 30 years that achieves its effect through a unique therapeutic pathway.

© 2024 MJH Life Sciences

All rights reserved.